Climb Bio jumps after $110 mln share placement
28/04/2026 12:56
** Climb Bio's CLYM.O shares jump 9.1% premarket to $10.37 after $110 mln equity raise news ** CLYM says it sold ~9.48 mln shares and pre-funded warrants to buy ~2.1 mln shares in private placement at $9.50, which is in line with stock's last close ** New and existing investors participated in placement including the likes of Adage Capital Partners, ADAR1 Capital Management, RA Capital Management, among other institutional investors, co says ** Leerink and Piper Sandler lead placement agents ** Earlier this month, U.S. FDA granted fast-track status to CLYM's experimental drug, budoprutug, for primary membranous nephropathy, a rare kidney disease with no FDA-approved treatments ** CLYM shares rose 4% on Mon, extending YTD gain to 137.5% YTD inclusive of 39% surge in Apr ** Wellesley Hills, Massachusetts-based CLYM has ~47.8 mln shares outstanding for roughly $450 mln market cap ** Of 13 analysts covering CLYM, 7 rate "strong buy", 6 recommend "buy"; median PT $16, according to LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380))